(17 days)
The Intersept filtered cardiotomy reservoir with Cortive surface is indicated for use in the cardiopulmonary bypass circuit during surgery for:
- an air/fluid separation chamber
- a temporary storage reservoir for priming solution and blood
- the filtration of particulates from bank blood and the storage and filtration of blood recovered from the field by suction
- the addition of medications or other fluids.
The Intersept Filtered Cardiotomy Reservoir with Cortiva BioActive Surface is a single-use, device with a sterile, nonpyrogenic fluid path. The maximum capacity of each reservoir is 2,600 mL. The maximum recommended flow rate is 2 liters per minute (LPM). Each reservoir has eight luer or 0.6 cm (0.25 in) ID access ports; four suction access ports, two pre-defoamer and two post-defoamer access ports. One of the post-defoamer access ports is intended for use as a vent. Each Intersept Filtered Cardiotomy Reservoir contains an open cell polyurethane defoamer with a 20-micron microaggregate filter covered with a polyester sleeve.
The provided document is a 510(k) premarket notification for a medical device, the "Intersept™ Filtered Cardiotomy Reservoir with Cortiva™ BioActive Surface." It details the device's indications for use, comparison to predicate devices, and a summary of testing conducted to demonstrate substantial equivalence.
However, this document does not contain the kind of detailed information typically found in acceptance criteria or a study write-up designed to prove a device meets those criteria, especially in the context of an AI-powered diagnostic device performing a specific task (like identifying lesions in medical images).
Here's why and what information is missing:
- Device Type: This submission is for a physical medical device (a cardiopulmonary bypass blood reservoir), not an AI algorithm. Therefore, the "acceptance criteria" and "study" described in the prompt, which are strongly geared towards AI performance metrics (sensitivity, specificity, AUROC, reader studies, ground truth establishment), don't directly apply in the same way.
- Performance Metrics: The "reported device performance" in this document refers to physical and biological performance (bioactivity, leaching, coverage, biocompatibility, filtration efficiency, blood trauma), not diagnostic accuracy.
- Clinical Study Design: There is no description of a clinical study involving human subjects or experts assessing diagnostic performance as would be relevant for an AI algorithm. The testing described is laboratory-based and focused on material properties and basic device function.
Based on the provided document, here's what can be extracted and what remains unanswered regarding the prompt's specific requests (assuming the prompt's structure is still applied, despite the mismatch in device type):
1. A table of acceptance criteria and the reported device performance
| Acceptance Criteria (Proxy from "Change" in document) | Reported Device Performance ("Results" in document) |
|---|---|
| Cortiva Coating Process Change (Bioactivity) | Pass |
| Cortiva Coating Process Change (Leaching) | Pass |
| Cortiva Coating Process Change (Coverage) | Pass |
| Alternate Material Formulation Change (Biocompatibility) | Pass |
| Alternate Material Formulation Change (Filtration Efficiency) | Pass |
| Alternate Material Formulation Change (Blood Trauma) | Pass |
Interpretation/Note: These are not "acceptance criteria" in the sense of diagnostic performance thresholds for an AI, but rather verification/validation checks for physical and biological device properties. The "Pass" indicates the device met Medtronic's internal criteria for these tests.
2. Sample sized used for the test set and the data provenance
- Sample Size for Test Set: Not specified in the provided document. The document lists "tests" but doesn't detail the number of units or samples used for each test.
- Data Provenance (e.g., country of origin of the data, retrospective or prospective): Not applicable for a physical device's lab testing. The tests are laboratory-based and not derived from clinical patient data from a specific country or study type.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
- This question is not applicable as the device is not an AI diagnostic algorithm, and "ground truth" in the context of medical image interpretation by experts is not relevant to this submission. The tests performed are laboratory-based physical and biological assays.
4. Adjudication method (e.g., 2+1, 3+1, none) for the test set
- Not applicable. There is no adjudication process involving human interpretation or consensus for the validation of this physical device. Verification/validation tests are typically performed according to established protocols.
5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
- Not applicable. This device is not an AI algorithm, and therefore, an MRMC study comparing human reader performance with and without AI assistance was not performed.
6. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done
- Not applicable. The device is a physical medical device, not an algorithm.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)
- Not applicable / Differently Defined: "Ground truth" for this device refers to established scientific/engineering principles, validated analytical methods, and predetermined specifications for physical and biological characteristics (e.g., certain levels of bioactivity, filtration efficiency, or absence of harmful leaching). It's not clinical "ground truth" derived from patient outcomes or expert reads.
8. The sample size for the training set
- Not applicable. This device is not an AI algorithm that requires a training set. The development of the device would involve engineering design, material selection, and iterative testing, not "training."
9. How the ground truth for the training set was established
- Not applicable. As above, no training set or its associated ground truth establishment is relevant to this physical device submission.
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" written around the top half of the circle. The bottom half of the circle contains a stylized image of a bird.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
March 17, 2017
Medtronic, Inc. Gayatri Ghadge Regulatory Affairs Specialist 710 Medtronic Parkway Minneapolis, MN 55432-5604
Re: K170583
Trade/Device Name: Intersept™ Filtered Cardiotomy Reservoir with Cortiva™ BioActive Surface Regulation Number: 21 CFR 870.4400 Regulation Name: Cardiopulmonary Bypass Blood Reservoir Regulatory Class: Class II Product Code: DTN, DTP
Received: February 28, 2017
Dated: February 27, 2017
Dear Ms. Ghadge:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
{1}------------------------------------------------
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely,
M.A. Hilleman
for Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known)
Device Name
Intersept™ Filtered Cardiotomy Reservoir with Cortiva™ BioActive surface
Indications for Use (Describe)
The Intersept filtered cardiotomy reservoir with Cortive surface is indicated for use in the cardiopulmonary bypass circuit during surgery for:
· an air/fluid separation chamber
- · a temporary storage reservoir for priming solution and blood
- the filtration of particulates from bank blood and the storage and filtration of blood recovered from the field by suction
- · the addition of medications or other fluids.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ☒ Prescription Use (Part 21 CFR 801 Subpart D) | □ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
Page 1 of 1
{3}------------------------------------------------
510(k) Summary
| Date Prepared: | February 27, 2017 |
|---|---|
| Applicant: | Medtronic, Inc.Medtronic Perfusion Systems7611 Northland DriveMinneapolis, MN 55428Establishment Registration Number: 2184009 |
| Contact Person: | Gayatri GhadgeRegulatory Affairs SpecialistMedtronic Perfusion SystemsPhone: 763.526.9336Fax: 763.367.8361Email: gayatri.a.ghadge@medtronic.com |
| Alternate Contacts: | |
| Chelsea PioskeSenior Regulatory Affairs SupervisorMedtronic Perfusion SystemsPhone: 763.514.9838Fax: 763.367.8360Email: chelsea.pioske@medtronic.com | |
| Jake RoellerSenior Regulatory Affairs ManagerMedtronic Perfusion SystemsPhone: 763.526.0404Fax: 763.367.8360Email: jake.w.roeller@medtronic.com |
Device Name and Classification
| Trade Name: | Intersept™ Filtered Cardiotomy Reservoir with Cortiva™BioActive Surface |
|---|---|
| Classification Name: | Reservoir, Blood, Cardiopulmonary Bypass; Defoamer,Cardiopulmonary Bypass |
| Regulation Number: | 21 CFR 870.4400 |
| Product Classification: | Class II |
| Product Code: | DTN, DTP |
{4}------------------------------------------------
Name of Predicate Devices: Intersept™ Filtered Cardiotomy Reservoir
Intersept® Filtered Cardiotomy Reservoir with Medtronic/Carmeda® BioActive Surface
Device Description
The Intersept Filtered Cardiotomy Reservoir with Cortiva BioActive Surface is a single-use, device with a sterile, nonpyrogenic fluid path. The maximum capacity of each reservoir is 2,600 mL. The maximum recommended flow rate is 2 liters per minute (LPM).
Each reservoir has eight luer or 0.6 cm (0.25 in) ID access ports;
- four suction access ports
- two pre-defoamer and ●
- two post-defoamer access ports. One of the post-defoamer access ports is intended for use ● as a vent.
Each Intersept Filtered Cardiotomy Reservoir contains an open cell polyurethane defoamer with a 20-micron microaggregate filter covered with a polyester sleeve.
Indications for Use
The Intersept filtered cardiotomy reservoir with Cortive surface is indicated for use in the cardiopulmonary bypass circuit during surgery for:
- an air/fluid separation chamber ●
- a temporary storage reservoir for priming solution and blood ●
- the filtration of particulates from bank blood and the storage and filtration of blood ● recovered from the field by suction
- the addition of medications or other fluids
Contraindications
Use the device only as indicated.
Predicate Devices
K926226 Intersent Filtered Cardiotomy Reservoir with Medtronic/Carmeda BioActive Surface
Premarket Notification submission K926226. for the Intersept Cardiotomy Reservoir with filter (model CB1351), was cleared for market by FDA on June 22, 1993. This submission was for the initial introduction of the Intersept Filtered Cardiotomy Reservoir with Carmeda BioActive Surface into the market.
{5}------------------------------------------------
K151110 Intersept Filtered Cardiotomy Reservoir
Premarket Notification submission K151110, for the Intersept Cardiotomy Reservoir with filter (model 1351), was cleared for market by FDA on May 27, 2015. This submission included a proposed alternate material formulation to the inner frames used within the Intersept Filtered Cardiotomy Reservoir, as well as a proposed Instructions for Use/labeling change.
Comparison to Predicate Devices
A comparison of the Intersept Filtered Cardiotomy Reservoir with Cortiva BioActive Surface to the predicate device (the Intersept Cardiotomy Reservoir with Filter and Intersept Filtered Cardiotomy Reservoir with Medtronic/Carmeda BioActive Surface) indicates the following similarities:
- Intended Use: The intended use is the same as predicate device.
- Design: The overall design is the same as the predicate. ●
- Materials: The material types used are the same as the predicate.
- The proposed modification in this submission from the predicate device is to an O alternate material formulation to the inner frame used within the Intersept Filtered Cardiotomy Reservoir.
- Principles of Operation and Technology: The principles of operation are the same as the ● predicate device.
- Performance: The performance is substantially equivalent to the predicate device.
- Coating: The Cortiva coating is the same as the predicate.
- The proposed modification in the submission from the predicate device includes: O slight alterations to the process steps and solution concentrations of the coating. This includes the alteration to coating process of the defoamer frame assembly inside the reservoir jar; and the filtration sock assembly inside a container.
Summary of Testing
Testing has demonstrated that the Intersept Filtered Cardiotomy Reservoir with Cortiva BioActive Surface is substantially equivalent to the predicate.
| Change | Verification/Validation | Results |
|---|---|---|
| Cortiva Coating Process Change | Bioactivity | Pass |
| Leaching | Pass | |
| Coverage | Pass | |
| Alternate Material Formulation Change | Biocompatibility | Pass |
| Filtration Efficiency | Pass | |
| Blood Trauma | Pass |
The following tests were conducted:
{6}------------------------------------------------
Conclusion
The data included in this submission is sufficient to provide reasonable assurance that the Intersept Filtered Cardiotomy Reservoir with Cortiva BioActive Surface is substantially equivalent to the legally marketed predicate device, the Intersept Filtered Cardiotomy Reservoir with Medtronic/Carmeda BioActive Surface and Intersept Filtered Cardiotomy Reservoir.
§ 870.4400 Cardiopulmonary bypass blood reservoir.
(a)
Identification. A cardiopulmonary bypass blood reservoir is a device used in conjunction with short-term extracorporeal circulation devices to hold a reserve supply of blood in the bypass circulation.(b)
Classification. Class II (special controls), except that a reservoir that contains a defoamer or filter is classified into the same class as the defoamer or filter. The device, when it is a cardiopulmonary bypass blood reservoir that does not contain defoamers or blood filters, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 870.9.